Format

Send to

Choose Destination

See 1 citation found by title matching your search:

See comment in PubMed Commons below
J Cyst Fibros. 2016 Nov;15(6):745-751. doi: 10.1016/j.jcf.2016.06.005. Epub 2016 Jun 21.

A novel guluronate oligomer improves intestinal transit and survival in cystic fibrosis mice.

Author information

  • 1Department of Genetics and Genome Sciences, Case Western Reserve University, United States.
  • 2Department of Pediatrics, Case Western Reserve University, United States.
  • 3AlgiPharma AS, Norway.
  • 4Department of Genetics and Genome Sciences, Case Western Reserve University, United States; Department of Pediatrics, Case Western Reserve University, United States.

Abstract

BACKGROUND:

Cystic fibrosis (CF) patients experience intestinal complications characterized by the accumulation of thick viscous mucus. CF mice were utilized to determine if a novel guluronate oligomer, OligoG, may be a potential therapy in reducing intestinal mucus and subsequent CF-related intestinal manifestations.

METHODS:

Intestinal transit, intestinal histology, survival and growth were examined in wildtype and CF mice on regular water and OligoG.

CONCLUSIONS:

OligoG improves intestinal transit and survival in CF mice by reducing the accumulation of intestinal mucus. OligoG's ability to directly bind mucin, disrupt mucin interaction and/or sequester calcium allowing for mucin expansion may explain the decrease in mucus accumulation.

KEYWORDS:

Cystic fibrosis; Genetically modified mouse; Intestinal transit; Mucus

PMID:
27343003
DOI:
10.1016/j.jcf.2016.06.005
[PubMed - in process]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center